Pfizer: JAK1 inhibitor Xibico has been approved as a new indication for age extension in China. Pfizer announced that the highly selective JAK1 inhibitor and innovative oral small molecule targeted drug Xibico have been officially approved by the National Medical Products Administration (NMPA) of China for the treatment of moderate to severe atopic dermatitis in adolescents and adults aged 12 and above.